Currency In USD
| Previous Close | 12.22 |
| Open | 12.44 |
| Day High | 12.51 |
| Day Low | 12.12 |
| 52-Week High | 16.76 |
| 52-Week Low | 9.85 |
| Volume | 33,885.38 |
| Average Volume | 141,662 |
| Market Cap | 422.21M |
| PE | -10.78 |
| EPS | -1.14 |
| Moving Average 50 Days | 12.66 |
| Moving Average 200 Days | 12.09 |
| Change | 0.07 |
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
GlobeNewswire Inc.
Mar 10, 2026 11:00 AM GMT
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence a
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose B
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
GlobeNewswire Inc.
Feb 23, 2026 12:00 PM GMT
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results